Katelyn R. Ludwig

Katelyn R. Ludwig

Auto-generated profile, based on publicly available information

Katelyn R. Ludwig

University of Colorado Boulder, Boulder, Colorado, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
ALAbigail G. Longtine
Abigail G. Longtine
RVRavinandan Venkatasubramanian
Ravinandan Venkatasubramanian
MZMelanie C. Zigler
Melanie C. Zigler
ALAlexandra J. Lindquist
Alexandra J. Lindquist
SMSophia A. Mahoney
Sophia A. Mahoney
ZCZachary S Clayton
Zachary S Clayton
Our study demonstrates that with aging, female C57BL/6N mice exhibit higher in vivo aortic stiffness, reduced modulus of elasticity, aortic wall structural and extracellular matrix remodeling, and elevations in systemic inflammation. These changes are largely reflective of those that occur with aging in women. Thus, female C57BL/6N mice are a viable model of human aortic aging and the utility of these animals should be considered in future biomedical investigations.

24 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
VCVictor J. Collins
Victor J. Collins
KLKatelyn R. Ludwig
Katelyn R. Ludwig
ANAriana E. Nelson
Ariana E. Nelson
SRSoumya Sundara Rajan
Soumya Sundara Rajan
CYChoh Yeung
Choh Yeung
CHChristine Heske
Christine Heske
Disruption of DNA damage repair via impaired homologous recombination is characteristic of Ewing sarcoma (EWS) cells. We hypothesize that this disruption results in increased reliance on nonhomologous end joining to repair DNA damage. In this study, we investigated if pharmacologic inhibition of the enzyme responsible for nonhomologous end joining, the DNA-PK holoenzyme, alters the response of EWS cells to genotoxic standard of care chemotherapy. We used analyses of cell viability and proliferation to investigate the effects of clinical DNA-PK inhibitors (DNA-PKi) in combination with six therapeutic or experimental agents for EWS. We performed calculations of synergy using the Loewe additivity model. Immunoblotting evaluated treatment effects on DNA-PK, DNA damage, and apoptosis. Flow cytometric analyses evaluated effects on cell cycle and fate. We used orthotopic xenograft models to interrogate tolerability, drug mechanism, and efficacy in vivo. DNA-PKi demonstrated on-target activity, reducing phosphorylated DNA-PK levels in EWS cells. DNA-PKi sensitized EWS cell lines to agents that function as topoisomerase 2 (TOP2) poisons and enhanced the DNA damage induced by TOP2 poisons. Nanomolar concentrations of single-agent TOP2 poisons induced G2M arrest and little apoptotic response while adding DNA-PKi-mediated apoptosis. In vivo, the combination of AZD7648 and etoposide had limited tolerability but resulted in enhanced DNA damage, apoptosis, and EWS tumor shrinkage. The combination of DNA-PKi with standard of care TOP2 poisons in EWS models is synergistic, enhances DNA damage and cell death, and may form the basis of a promising future therapeutic strategy for EWS.

17 June 2026
Verified
Other
Open access
VCVictor J. Collins
Victor J. Collins
KLKatelyn R. Ludwig
Katelyn R. Ludwig
ANAriana E. Nelson
Ariana E. Nelson
SRSoumya Sundara Rajan
Soumya Sundara Rajan
CYChoh Yeung
Choh Yeung
CHChristine Heske
Christine Heske
Concomitant AZD-7648 and etoposide treatments impair tumor growth

17 June 2026
Verified
Other
Open access
VCVictor J. Collins
Victor J. Collins
KLKatelyn R. Ludwig
Katelyn R. Ludwig
ANAriana E. Nelson
Ariana E. Nelson
SRSoumya Sundara Rajan
Soumya Sundara Rajan
CYChoh Yeung
Choh Yeung
CHChristine Heske
Christine Heske
In vivo compound preparation and administration information

17 June 2026
Verified
Other
Open access
PDF file
VCVictor J. Collins
Victor J. Collins
KLKatelyn R. Ludwig
Katelyn R. Ludwig
ANAriana E. Nelson
Ariana E. Nelson
SRSoumya Sundara Rajan
Soumya Sundara Rajan
CYChoh Yeung
Choh Yeung
CHChristine Heske
Christine Heske
Evaluation of the DNA-PK inhibitors plus TOP2 poisons in preclinical models of EWS

17 June 2026
Verified
Other
Open access
PDF file
VCVictor J. Collins
Victor J. Collins
KLKatelyn R. Ludwig
Katelyn R. Ludwig
ANAriana E. Nelson
Ariana E. Nelson
SRSoumya Sundara Rajan
Soumya Sundara Rajan
CYChoh Yeung
Choh Yeung
CHChristine Heske
Christine Heske
A screen of multiple drug combinations demonstrates the selectivity of the synergistic activity of the DNA-PK clinical inhibitor M3814